Boehringer reports Phase III mild asthma data; no word on NDA filing
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim has now reported Phase III data for tiotropium delivered via the Respimat inhaler device for severe, moderate and mild asthma patients, but the German drug maker has not revealed when it will file for US FDA approval.